becton dickinson co januari
becton dickinson co buy
new product launch motiv revenu across segment
maintain buy rate bd upgrad tp
perviou tp deriv tp
ep forward look pe
provid upsid potenti
expect top-lin revenu growth
compani perform well consid new product
launch segment continu double-digit
growth emerg market achiev carefus
cost synergi end
number in-lin crispidea estim
mn except ep
becton dickinson co report strong net incom ep
growth bd also end strong number
revenu net incom compani also complet
acquisit bard emerg market grew double-digit
bd revenu number quarter base strong
perform diabet across life
scienc segment combin continu strength
emerg market three year end fiscal
cumul basi compani achiev underli margin
expans basi point
bd significantli expand margin captur
addit annual synergi cost save relat
carefus reach annual cost save
cumul basi end fiscal
compani namebecton dickinson companytickerbdxstock ratingbuyunchangedindustri viewoverweightpositivepric jan week week volum volum ep margin margin ttm per share growth profit ttm ttm incom ttm earn growth becton dickinson co januari
incom statement
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
becton dickinson co januari
revenu quarter stood
compar decreas
y/i due divestitur respiratori solut
busi octob revenu stood
compar
decreas y/i decreas reflect
reduct revenu due divestitur
respiratori solut busi octob
geograph wise sale safety-
engin devic increas y/i
intern sale safety-engin devic
emerg market revenu growth
driven sale greater asia includ china
latin america unfavor foreign currenc translat
impact emerg market revenu
product revenu compar
increas y/i life scienc
segment safety-engin product revenu
compar increas
compani complet tuck-in acquisit flowjo
lead provid informat softwar flow cytometri
next-gener single-cel instrument
bd significantli expand margin captur
addit annual synergi cost save
relat carefus reach annual cost
save cumul basi end fiscal
oper net margin quarter
respect roa roe quarter
ep
stock price histori date high obsolet date obsolet move move share statist averag volum averag volum share held held share short short share short prior dividend split forward annual dividend forward annual dividend trail annual dividend trail annual dividend year averag dividend pay-out dividend date dec ex-dividend date dec last split factor new per last split date aug inform becton dickinson co januari
incom statement
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
becton dickinson co januari
non- reconcili refer pg
incom statement month end month end month end month end month end month end month end month end month end month end month end revenu total- total revenu gross selling/general/admin expens research depreciation/amortization- interest expens incom net operating- unusu expens oper expens total oper oper interest incom expens net non-operating- loss sale assets- incom incom minor interest- equiti affiliates- net incom extra account change- discontinu operations- extraordinari item- net prefer dividends- incom avail common excl extra incom avail common incl extra basic weight averag shares- basic ep exclud extraordinari items- basic ep includ extraordinari items- dilut adjustment- dilut weight averag dilut ep exclud extraordinari dilut ep includ extraordinari items- dividend per share common stock primari gross dividend common stock- net incom stock base comp expense- basic ep stock base comp expsense- dilut ep stock base comp expense- depreci supplemental- total special items- normal incom taxes- effect special item incom taxes- incom tax ex impact special items- normal incom taxes- normal incom avail common- basic normal eps- dilut normal actual annual estim annual actual quarterli becton dickinson co januari
 term short term receiv trade receiv current asset current total term long term asset payable/short term port lt debt/capit current liabil current term leas long term incom liabil prefer stock stock non redeem stock paid-in earn accumul stock equiti liabil sharehold out common stock primari common share annual actual quarterli balanc sheet item becton dickinson co januari
cash equival compar
flow financ activ compar due
issuanc senior unsecur note equiti secur
bd repurchas million common stock acceler share
repurchas agreement
month end month end month end month end month end month end month end month end income/start work oper invest item invest dividend retir stock retir debt financ exchang chang interest paid tax paid becton dickinson co januari
becton dickinson co report strong net incom ep growth
bd also end strong number revenu net incom
compani also complet acquisit bard emerg market grew
double-digit adjust ep quarter beat
zack consensu estim
revenu quarter stood compar
decreas y/i due divestitur respiratori
solut busi octob
cog quarter compar decreas
y/i gross margin increas compar
increas favor impact busi
divestitur primarili divestitur respiratori solut busi
product rel lower gross profit margin
sg quarter compar
decreas y/i sg expens percentag revenu
quarter reflect impact lower revenu
 expens quarter compar
decreas y/i primarili due time expens
acquisit restructur quarter decreas
y/i compar
ebit quarter compar
increas mainli due increas revenu pair decreas oper
cost quarter
net incom compar
increas mainli due increas oper incom ep
compar
revenu
quarter stood
compar
decreas y/i
 expens
quarter
compar
decreas
net incom
compar
increas
mainli due
incom ep
compar
becton dickinson co januari
safeti revenu total safeti revenu quarter compar
decreas y/i total revenu full year
increas y/i
geograph wise sale safety-engin devic
increas y/i intern sale safety-engin devic
increas y/i
segment wise medic segment safety-engin product revenu
quarter compar increas y/i life scienc
segment safety-engin product revenu quarter
compar increas y/i
safeti revenu
total safeti revenu
quarter
compar
revenu quarter
compar
increas
revenu quarter
compar
increas y/i
becton dickinson co januari
revenu stood compar
decreas y/i decreas reflect reduct
revenu due divestitur respiratori solut busi octob
volum growth continu busi
partial off-set unfavor impact foreign currenc
translat less price materi impact revenu
cog compar decreas y/i
gross margin increas compar
increas primarili reflect lower manufactur cost result
continu oper improv project gross profit margin
favor impact busi divestitur primarili divestitur
respiratori solut busi product rel lower gross
sg compar decreas
y/i sg expens percentag revenu rel flat
compar
 expens compar
decreas y/i percentag revenu slightli
lower compar reflect favor comparison
includ increas invest high growth opportun
acquisit restructur quarter decreas
y/i compar cost repres integr
restructur cost substanti associ acquisit
carefus portfolio ration initi
oper expens includ non-cash charg result
modif dispens equip leas contract
ebit quarter compar
increas mainli due decreas oper cost partli off-set decreas
revenu
stood
compar
decreas y/i
cog
compar
gross margin increas
compar
acquisit
restructur
quarter
decreas y/i
compar
becton dickinson co januari
net incom compar
increas y/i increas mainli due increas oper
incom tax benefit record ep
compar increas y/i
safeti revenu total safeti revenu compar
increas y/i
geograph wise sale safety-engin devic
increas y/i intern sale safety-engin
devic increas y/i
segment wise medic segment safety-engin product revenu
compar increas y/i life
scienc segment safety-engin product revenu
compar increas y/i
safeti revenu
net incom
compar
increas mainli due
incom tax benefit
record
ep
compar
increas
sale
increas
y/i
intern sale
increas
 revenu
quarter
compar
y/i primarili due
divestitur
busi octob
quarter
compar
revenu
emerg
driven
sale greater asia
includ china
becton dickinson co januari
 revenu quarter compar
decreas y/i primarili due divestitur respiratori solut
busi compar basi revenu increas includ
estim advers impact chang dispens busi
model within bd medic segment growth medic
manag solut diabet pharmaceut system unit
partial off-set declin medic procedur solut unit
perform medic manag solut unit reflect strong growth
infus busi partial off-set impact chang
dispens busi model revenu medic procedur solut
unit declin due tough comparison prior year bd life scienc
segment result reflect solid perform preanalyt system
bioscienc unit revenu diagnost system unit declin due
tough comparison prior year
revenu quarter compar
increas y/i reflect impact aforement
divestitur compar currency-neutr basi revenu outsid
increas revenu growth reflect strong perform
segment within bd medic segment growth driven strength
medic procedur solut medic manag solut
unit growth bd life scienc segment reflect strong perform across
bioscienc diagnost system preanalyt system unit
 revenu report decreas y/i primarili due
divestitur respiratori solut busi compar basi
revenu grew includ estim advers impact
chang dispens busi model report revenu outsid
 flat compar prior-year period primarili due
divestitur respiratori solut busi compar currency-
neutral basi revenu outsid grew
emerg market revenu emerg market revenu
growth driven sale greater asia includ china latin
revenu estim
becton dickinson co januari
compani organiz structur base upon two princip busi
segment bd medic bd life scienc
total revenu
medic segment
quarter
compar
total revenu medic segment quarter compar
decreas y/i primarili due divestitur
respiratori solut busi octob compar
currency-neutr basi revenu increas includ estim
advers impact chang dispens busi model
perform
diabet unit
solid perform
pharmaceut
total revenu
medic segment
compar
segment result reflect strong perform medic manag
solut diabet unit solid perform
system unit growth medic procedur solut unit reflect
tough comparison prior-year period perform medic
manag solut unit includ advers impact chang
total revenu medic segment compar
decreas y/i revenu growth driven
medic procedur solut unit sale infus dispos product
particularli intern market pharmaceut system unit sale
self-inject system revenu growth also reflect diabet
unit increas sale pen needl emerg market
growth diabet unit impact weaker revenu
europ primarili unit kingdom due increas pressur
govern payer part auster measur
revenu unfavor impact divestitur respiratori
solut busi modif dispens equip leas contract
custom medic manag solut unit took place
ebit compar increas
y/i oper margin compar
increas due divestitur respiratori solut busi
busi gener lower oper margin
becton dickinson co januari
total revenu life
scienc segment
quarter
compar
increas
total revenu life scienc segment quarter
compar increas y/i segment revenu
growth reflect strong perform across bioscienc diagnost system
preanalyt system unit
total revenu life scienc segment compar
increas y/i life scienc segment
revenu reflect growth global sale preanalyt system unit
safety-engin product growth sale diagnost system unit
microbiolog molecular platform particularli emerg market
segment revenu growth also driven increas bioscienc unit
sale particularli develop market
total revenu
life scienc
segment
compar
increas
life scienc segment oper incom driven perform
respect gross profit margin oper expens life scienc
segment gross profit margin percentag revenu lower fiscal year
primarili due unfavor foreign currenc translat higher raw
materi cost unfavor product mix partial off-set lower
manufactur cost result oper improv project
margin percentag
revenu lower
due unfavor
becton dickinson co januari
build portfolio fda approv sodium chlorid
system reagent
instrument
salin freseniu
launch bd rhapsodi complet singl cell analysi system reagent
instrument softwar
introduct new bd ultra-fin micro pen needl inject
acquisit flowjo
lead provid
informat softwar
flow cytometri next-
complet tuck-in acquisit flowjo lead provid informat
softwar flow cytometri next-gener single-cel instrument
timothi ring david melcher elect join bd board director
instal alari pump modul
achiev carefus cost synergi fy
compani on-track fy
on-track achiev carefus manufactur synergi fy
base plan effici synergi gener signific margin expans
synergi gener
becton dickinson co januari
launch
delay fy
launch
launch
launch
launch
launch
launch
launch
launch ec ca
ex-u china
launch
launch
launch
launch
launch
launch
becton dickinson co januari
bd venflon safeti bd instaflash needl
fy delay late fy
fy delay late fy
becton dickinson co januari
fiscal year bd expect adjust ep
reflect currency-neutr growth
bd expect revenu growth currency-neutr basi
repres strong underli growth exclud impact
 dispens chang
report basi revenu growth expect
reflect currenc tailwind assum euro dollar exchang
rate
bd expect bd medic grow also expect
life scienc segment grow
expect adjust ep
growth
revenu growth
expect
reflect
currenc tailwind
dollar exchang rate
becton dickinson co januari
bd revenu number quarter base strong perform
diabet across life scienc segment combin
continu strength emerg market three year end fiscal
cumul basi compani achiev underli margin expans
bd significantli expand margin captur addit
annual synergi cost save relat carefus reach
annual cost save cumul basi end fiscal
compani conduct clinic trial gather insight
ensur patient ultim realiz full benefit bd flowsmart
technolog bd continu work close toward full
within genom busi bd recent expand portfolio
launch bd rhapsodi new singl cell platform rna express
analysi bd soon abl provid sodium chlorid salin
custom partnership freseniu
oper net margin quarter respect
roa roe quarter ep
three year
end fiscal
cumul basi
expans basi
compani
gather insight
ensur
realiz full benefit
within genom
expand portfolio
launch bd
cell platform rna
becton dickinson co januari
non- reconcili
non- reconcili
oper tax oper tax becton dickinson co januari
incom statement
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
becton dickinson co januari
revenu growth compar
oper incom growth compar
gross margin flat compar
ratio revenu margin margin inc margin rate margin turnov averag asset leverag averag equiti year averag averag averag year averag averag averag year averag averag averag growth growth ex sale /sale /net incom ratio profit marginsprofitabilityrevenu growth oper incom growthep growth becton dickinson co januari
mrqgross mrqcog mrqsg mrqr mrqnet mrqoper margin becton dickinson co januari
inv flow sale
mrqreturn mrqcapex salescap ex salesfre mrq ratio growth yoy oper growth yoy free growth mrqreturn mrqfinanci mrqyoy growth revenu growthoper incom growthep growth becton dickinson co januari
per share item ratio
fiscal per per per per share cash-flow per per valu per book per end stock end stock equiti asset invest capit capit joel greenblatt margin margin margin equiti total debt total pay-out sale account convers rate incom incom margin itemsquarterli item becton dickinson co januari
balanc sheet item
outstand equival market properti plant properti plant issuanc prefer issuanc chang becton dickinson co januari
incom statement
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
becton dickinson co januari
breakdown share held insid share held institut mutual fund float held institut mutual fund institut hold direct holder form vincent gari wilard bertram jame gari ribo jeffrey institut holdersholdershar report outvaluepric row associ vanguard group inc fmr jp morgan wellington manag compani well fargo putnam invest top mutual fund holdersholdersharesd report outvaluevanguard total stock market vanguard price row growth stock fund price row capit appreci franklin manag trust rise dividend price row chip growth fund spdr etf vanguard institut fund-institut price row fidel select portfolio medic equip becton dickinson co januari
compani name/symbolcurr consensu recommendationpricemarket yr ep growthbecton dickinson bard minor becton dickinson co januari
developmentsbd get final regulatori approv bard acquisitionon decemb becton dickinson compani receiv clearanc bard bcr acquisit form mofcom ministri commerc peopl republ china approv conting divest bd soft tissu core needl biopsi product line acquisit expect complet decemb divest soft tissu core needl biopsi product line merit medic conting mofcom approv becton dickinson bard receiv regulatori nod chinath ministri commerc peopl republ china approv becton dickinson compani acquisit bard bcr compani set complet cash-and-stock deal becton dickinson focus medic manag dec becton dickinson compani popularli known bd recent enhanc medic manag process technolog innov compani introduc innov platform like bd healthsight viewer bd pyxi es softwar bd alari infus solut promis inventori optim avail solid clinician product complet medic safeti patient impact dispens busi chang bd revenu bd introduc chang us dispens busi part effort transform medic manag solut initi impact compani perform due relat account chang chang higher-than-expect impact impact compani revenu basi point fiscal becton dickinson co januari
incom statement
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
becton dickinson co januari
ytd stock perform
bd
outperform
price-to-earnings ratio bd
decreas industri
average
actual vs price-to-earnings ratio ttm price-to-earnings high last yr price-to-earnings last yr beta price sale ttm price book mrq price ttm price free ttm errorerrorerror own dividend yield dividend yield year average dividend year growth rate pay-out ratio ttm sale mrq vs qtr yr sale ttm vs ttm yr sale yr growth rate sale yr growth rate ep mrq vs qtr yr ep ttm vs ttm yr ep yr growth rate ep yr growth rate capit spend yr growth rate lt debt equiti mrq total debt equiti mrq interest coverag ttm gross margin ttm gross margin yr average ebitd margin ttm ebitd yr average oper margin ttm oper margin yr average pre-tax margin ttm pre-tax margin yr average net profit margin ttm net profit margin yr average effect tax rate ttm effect tax rate yr average return asset ttm return asset yr average return invest ttm return invest yr average return equiti ttm return equiti yr average revenue/employe ttm net income/employe ttm receiv turnov ttm inventori turnov ttm asset turnov ttm manag effect effici performancevalu ratio dividend growth rate ratio profit becton dickinson co januari
consensu view analyst trend stock
growth rate
bd in-
line average
forward price-to-earnings
bd also in-lin
 average
bdx avgfive-year growth forecast usdgrowth high day day day estim comparisonbdxindustri avg avgprice/earn yield becton dickinson co januari
consensu view analyst trend stock
earn growth
respect
revenu growth
respect
adjust ep expect
estimatescurr analyst estimatethi estim estimatepast ep growthprice/earningsobsoleteobsoleteobsoleteobsoletepeg ratioobsoleteobsoleteobsoleteobsoleteconsensu ep day day day day ep last last last daysn/an/an/an/adown last dayscurr growth ratescurr surprisescurr becton dickinson co januari
price target summarycrispidea jamesupgradestrong isi groupupgradeoutperformrecommend trendscurr monthlast monthtwo month agothre month agostrong estcurr qtr next qtrcurrent yearnext estcurr qtr next qtrcurrent yearnext becton dickinson co januari
incom statement
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
becton dickinson co januari
stock surg due strong result
stock given return last month
 price movementvolumeclos becton dickinson co januari
stock seen consist rise price low sinc jan
stock reach high dec given total return last year
 price movementvolumeclos becton dickinson co januari
year chart show rise price stock level level given total
return last year
stock averag trade volum rel flat
 year price movementvolumeclos becton dickinson co januari
crispidea financi inform servic firm focus provid equiti research portfolio manag
person wealth manag brokerag servic inform servic side provid commun
consult research servic host client
crispidea track limit number compani sector strive provid qualiti insight straight
forward analysi object creat long-term wealth moder low risk crispidea leverag
larg number in-hous extern expert oper within industri strong financi oper
strateg background
detail visit www crispidea com contact
